CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2018 , the Compensation Committee of Sage’s
On track to submit New Drug Application for brexanolone for postpartum depression in 1H 2018 following pre-NDA meeting; buildout of commercial infrastructure underway for potential 1H 2019 launch Breakthrough Therapy designation for SAGE-217 offers potential for expedited development of major
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,506,098
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $575.0
– Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from depression – – Sage has received two Breakthrough Therapy designations for separate psychiatric drug candidates, reinforcing the Company’s
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2018 , the Compensation Committee of Sage’s
– SAGE-217 met primary endpoint of improved sleep efficiency and demonstrated improvements in maintaining sleep compared to placebo – – Secondary endpoint measures demonstrated clear dose response with statistical significance in total sleep time and time spent awake after sleep onset – – Data
– Company evolving, as planned, to be a leading, innovative CNS company – – 2018 strategy focuses on continued R&D innovation, pipeline expansion and commercialization plans for new classes of CNS therapeutics – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.
